Status:

COMPLETED

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

Lead Sponsor:

National Taiwan University Hospital

Conditions:

Non-small Cell Lung Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens: weekly docetaxel plus cisplatin followed by gemcitabine; and gemcitabine plus cispla...

Detailed Description

Lung cancer is the leading cause of cancer death in men and women worldwide. Shifting trends in the incidence of lung cancer closely follow the patterns of cigarette smoking, although other carcinogen...

Eligibility Criteria

Inclusion

  • Histologic or cytologic diagnosis of stage IIIB/IV NSCLC, no prior chemotherapy
  • Age \> 18 years and \< 75 years
  • WHO PS: 0,1
  • Unidimensional or bi-dimensional measurable disease
  • Neutrophils \> 1.5 109/l, Platelets \> 100 109/l, Hemoglobin \> 10g/dl, Total bilirubin \< 1.5 UNL, AST (SGOT) and ALT (SGPT) \< 2.5 UNL, Alkaline phosphatases \< 5 UNL; except in presence of only bone metastasis and in the absence of any liver disorders
  • Creatinine \< 1 UNL, and creatinine clearance should be \> 60 ml/min.
  • Life expectancy \> 12 weeks

Exclusion

  • Pregnant, or lactating patients
  • Known clinical brain or leptomeningeal involvement
  • Pre-existing motor or sensory neurotoxicity of a severity \> grade 1 by NCIC-CTG criteria
  • CHF, angina or arrhythmias
  • History of significant neurological or psychiatric disorders
  • Active uncontrolled infection
  • Contraindication for the use of corticosteroids
  • Concurrent treatment with other experimental drugs within 30 days prior to study entry
  • Concurrent treatment with any other anti-cancer therapy

Key Trial Info

Start Date :

July 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2012

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00173888

Start Date

July 1 2003

End Date

November 1 2012

Last Update

December 6 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Oncology, National Taiwan University Hospital

Taipei, Taiwan

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC) | DecenTrialz